The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Abstract
IMPORTANCE: Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in patients with preexisting autoimmune disorders is not known. OBJECTIVE: To determine the safety and efficacy of ipilimumab therapy in patients with advanced melanoma with preexisting autoimmune disorders. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of patients with advanced melanoma and preexisting autoimmune disorders who received ipilimumab at 9 academic tertiary referral centers from January 1, 2012, through August 1, 2015. The data analysis was performed on August 24, 2015. EXPOSURE: Ipilimumab therapy. MAIN OUTCOMES AND MEASURES: Safety, in terms of frequency of autoimmune flares and conventional immune-related adverse events (irAEs), and efficacy, in terms of response rates and overall survival, were evaluated descriptively. RESULTS: Of the 30 patients who received ipilimumab (17 [57%] male; median [range] age, 59.5 [30-80] y), 6 had rheumatoid arthritis, 5 had psoriasis, 6 had inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmune thyroiditis, and 7 had other conditions. Thirteen patients (43%) were receiving immunosuppressive therapy at the time of initiation of ipilimumab therapy, most commonly low-dose prednisone or hydroxychloroquine. With ipilimumab treatment, 8 patients (27%) experienced exacerbations of their autoimmune condition necessitating systemic treatment; all were managed with corticosteroids. Conventional grade 3 to 5 irAEs occurred in 10 patients (33%) and were reversible with corticosteroids or with infliximab therapy in 2 cases. One patient with baseline psoriasis died of presumed immune-related colitis after a 1-week delay prior to reporting symptoms. Fifteen patients (50%) had neither autoimmune disease flares nor irAEs. Six patients experienced an objective response (20%), including 1 with a durable complete response. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the largest series of patients with preexisting autoimmune disease treated with immune checkpoint inhibitors. Ipilimumab was clinically active and was associated with exacerbations of autoimmune disease and conventional ipilimumab-induced irAEs that were readily manageable with standard therapies when started in a timely fashion. Ipilimumab therapy may be considered in this setting with vigilant clinical monitoring.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Possible risk factors for ICI-related hepatotoxicity include organ transplantation, comorbidity with autoimmune disease, history of ICI-induced irAEs, high doses of ICIs (particularly cytotoxic T-lymphocyte antigen 4 inhibitors), combination therapy with multiple ICIs, or a combination of an ICI with targeted therapy [165][166][167].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [165]
In the citing paper
“Incidence of endocrine events varies based on type of ICI used (see Figure 2).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“Thyroid events occur in approximately 10% of patients treated with anti-PD-1/PD-L1 monotherapy, and up to 15-20% of those treated with combination PD-1/CTLA-4 blockade (as opposed to only 5% of those treated with ipilimumab monotherapy).9,38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
In the citing paper
“hypophysitis or hypopituitarism occurs in up to 10% of patients who receive anti-CTLA-4 based therapy (either with ipilimumab monotherapy, and slightly more commonly with combination CTLA-4/PD-1 blockade).38”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [38]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
The mortality of rheumatoid arthritis
Wolfe, F., Mitchell, D. M., Sibley, J. T., Fries, J. F., Bloch, D. A., Williams, C. A., Spitz, P. W., Haga, M., Kleinheksel, S. M., & Cathey, M. A. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370408 · Cited by 1,325
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 639
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
Tocut, M., Brenner, R. M., & Zandman‐Goddard, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.010 · Cited by 108
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Delaunay, M., Prévôt, G., Collot, S., Guilleminault, L., Didier, A. P., & Mazières, J. (2019) · European Respiratory Review · doi:10.1183/16000617.0012-2019 · Cited by 108
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras, C., Micheli, R. D., Moura, B. G., Hundsberger, T., & Hottinger, A. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0810-1 · Cited by 109
Feng, S., Coward, J. I. G., McCaffrey, E., Coucher, J., Kalokerinos, P. N., & O'Byrne, K. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.007 · Cited by 107
Checkpoint Inhibitor–Induced Colitis
Bellaguarda, E., & Hanauer, S. B. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000497 · Cited by 107
Classical Examples of the Concept of the ASIA Syndrome
Borba, V. V., Malkova, A. M., Basantsova, N. Y., Halpert, G., Andréoli, L., Tincani, A., Amital, H., & Shoenfeld, Y. (2020) · Biomolecules · doi:10.3390/biom10101436 · Cited by 106
Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H., & Svane, I. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.017 · Cited by 105
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 102
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102
Kehl, K. L., Yang, S., Awad, M. M., Palmer, N., Kohane, I. S., & Schrag, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02321-z · Cited by 100
Reuss, J. E., Kunk, P. R., Stowman, A. M., Gru, A. A., Slingluff, C. L., & Gaughan, E. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0199-9 · Cited by 97
Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
Reddy, H. G., Schneider, B. J., & Tai, A. W. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0049-9 · Cited by 95
van der Kooij, M. K., Suijkerbuijk, K. P. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., van Breeschoten, J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B. A. G., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-3419 · Cited by 95
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 95
Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
Smith, M. H., & Bass, A. R. (2017) · Arthritis Care & Research · doi:10.1002/acr.23467 · Cited by 94
Secondary causes of inflammatory bowel diseases
Ghouri, Y. A., Tahan, V., & Shen, B. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i28.3998 · Cited by 94
Jennings, J. J., Mandaliya, R. H., Nakshabandi, A., & Lewis, J. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1574744 · Cited by 94
How to manage patients with corticosteroids in oncology in the era of immunotherapy?
Aldea, M. D., Orillard, É., Mansi, L., Marabelle, A., Scotté, F., Lambotte, O., & Michot, J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.032 · Cited by 96
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 92
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 100
Michailidou, D., Khaki, A. R., Morelli, M. P., Diamantopoulos, L. N., Singh, N., & Grivas, P. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-88307-3 · Cited by 94
T cell exhaustion and immune-mediated disease — the potential for therapeutic exhaustion
McKinney, E. F., & Smith, K. G. C. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.09.005 · Cited by 91
Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 90
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 92
Cardiotoxicity of Immune Checkpoint Inhibitors
Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 89
Xie, W., Huang, H., Xiao, S., Fan, Y., Deng, X., & Zhang, Z. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102687 · Cited by 86
Regev, A., Avigan, M., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Bisceglie, A. M. D., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 86
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Ju, A., Tang, J., Chen, S., Fu, Y., & Luo, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.709077 · Cited by 83
Brown, L. J., Weppler, A. M., Bhave, P., Allayous, C., Patrinely, J. R., Ott, P. A., Sandhu, S. K., Haydon, A. M., Lebbé, C., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002121 · Cited by 83
Self-citationPredictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Y., Fu, Y., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02023 · Cited by 83
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 84
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81
Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
Collins, M., Soularue, É., Marthey, L., & Carbonnel, F. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.033 · Cited by 83
Meserve, J. D., Facciorusso, A., Holmer, A. K., Annese, V., Sandborn, W. J., & Singh, S. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16217 · Cited by 81
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky, W., Jilaveanu, L., Turner, N., Perry, C., Zito, C., Tomayko, M., Leventhal, J., Herold, K., Meffre, E., Bosenberg, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0613-1 · Cited by 78
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover, S., Dougan, M. L., Tyan, K., Giobbie‐Hurder, A., Blum, S. M., Ishizuka, J. J., Qazi, T., Elias, R., Vora, K. B., Ruan, A. B., et al. (2020) · Cancer · doi:10.1002/cncr.32966 · Cited by 77
Self-citationSupportive care for patients undergoing immunotherapy
Rapoport, B. L., Eeden, R. I. V., Sibaud, V., Epstein, J. B., Klastersky, J. A., Aapro, M., & Moodley, S. D. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3802-9 · Cited by 77
Immune checkpoint inhibitor colitis: the flip side of the wonder drugs
Assarzadegan, N., Montgomery, E. A., & Anders, R. A. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2267-z · Cited by 76
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75
Self-citationImmune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 77
de Oliveira, M. C. B., de Brito, M. H., & Simabukuro, M. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.538695 · Cited by 76
“How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
LeBlanc, T. W., Temel, J. S., & Helft, P. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201211 · Cited by 74
Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies
Villani, A., Fabbrocini, G., Costa, C., Annunziata, M. C., & Scalvenzi, M. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0288-z · Cited by 75
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
Calabrese, L. H., & Velcheti, V. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209782 · Cited by 75
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
Solimando, A. G., Crudele, L., Leone, P., Argentiero, A., Guarascio, M., Silvestris, N., Vacca, A., & Racanelli, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093054 · Cited by 73
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 74
Benfaremo, D., Manfredi, L., Luchetti, M. M., & Gabrielli, A. (2018) · Current Drug Safety · doi:10.2174/1574886313666180508122332 · Cited by 72
The impact of corticosteroid use during anti-PD1 treatment
Pan, E. Y., Merl, M. Y., & Lin, K. I. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219872786 · Cited by 72
O'Kane, G. M., Labbé, C., Doherty, M. K., Young, K., Albaba, H., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0164 · Cited by 72
Functionalized chitosan as a promising platform for cancer immunotherapy: A review
Liang, X., Mu, M., Fan, R., Zou, B., & Guo, G. F. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119452 · Cited by 71
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70
Kidney Complications of Immune Checkpoint Inhibitors: A Review
Shingarev, R. A., & Glezerman, I. G. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.03.433 · Cited by 72
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 70
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
Zhou, L., & Wei, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701951 · Cited by 72
Uemura, M. I., Trinh, V. A., Haymaker, C., Jackson, N. A., Kim, D. W., Allison, J. P., Sharma, P., Vence, L. M., Bernatchez, C., Hwu, P., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0309-7 · Cited by 69
Neuromuscular complications of immune checkpoint inhibitor therapy
Kolb, N., Trevino, C., Waheed, W., Sobhani, F., Landry, K. K., Thomas, A. A., & Hehir, M. (2018) · Muscle & Nerve · doi:10.1002/mus.26070 · Cited by 68
Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H. A. J., & Smit, E. F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.012 · Cited by 67
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
Halle, B. R., Warner, A. B., Zaman, F. Y., Haydon, A. M., Bhave, P., Dewan, A. K., Ye, F., Irlmeier, R. T., Mehta, P. P., Kurtansky, N. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003066 · Cited by 67
Self-citationA review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67
Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis
Hutchinson, J. A., Kronenberg, K., Riquelme, P., Wenzel, J. J., Glehr, G., Schilling, H., Zeman, F., Evert, K., Schmiedel, M., Mickler, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21572-y · Cited by 66
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180870 · Cited by 65
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Pan, P., & Haggiagi, A. M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0859-2 · Cited by 66
Joshi, U. M., Kashani–Sabet, M., & Kirkwood, J. M. (2025) · JAMA · doi:10.1001/jama.2025.13074 · Cited by 68
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018
Winthrop, K. L., Weinblatt, M. E., Crow, M. K., Burmester, G. R., Mease, P. J., So, A. K.-L., Bykerk, V. P., van Vollenhoven, R., Dougados, M., Kay, J., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214280 · Cited by 67
Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0986 · Cited by 64
Self-citationImmune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Aziz, M. A. A. E., Facciorusso, A., Nayfeh, T., Saadi, S. M., Elnaggar, M. Y., Cotsoglou, C., & Sacco, R. (2020) · Vaccines · doi:10.3390/vaccines8040616 · Cited by 65
Powell, N., Ibraheim, H., Raine, T., Speight, A., Papa, S., Brain, O., Green, M., Samaan, M., Spain, L. A., Yousaf, N., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30014-5 · Cited by 63
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma
Martini, A., Fallara, G., Pellegrino, F., Cirulli, G. O., Larcher, A., Necchi, A., Montorsi, F., & Umberto Capitanio, A. (2021) · World Journal of Urology · doi:10.1007/s00345-020-03550-z · Cited by 63
Poels, K., Neppelenbroek, S. I. M., Kersten, M. J., Antoni, M. L., Lutgens, E., & Seijkens, T. T. P. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002916 · Cited by 64
Toxicity profiles of immunotherapy
Cousin, S., Sénéschal, J., & Italiano, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.005 · Cited by 63
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 63
Self-citationHanna, G. J., Ruiz, E. S., LeBoeuf, N. R., Thakuria, M., Schmults, C. D., DeCaprio, J. A., & Silk, A. W. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01044-8 · Cited by 62
Keeping Expectations in Check With Immune Checkpoint Inhibitors
Temel, J. S., Gainor, J. F., Sullivan, R. J., & Greer, J. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2146 · Cited by 62
Self-citationChinese guideline for the diagnosis and treatment of drug-induced liver injury: an update
Mao, Y., Ma, S., Liu, C., Liu, X., Su, M., Li, D., Li, Y., Chen, G., Chen, J., Chen, J., et al. (2024) · Hepatology International · doi:10.1007/s12072-023-10633-7 · Cited by 62
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 62
Sun, M. M., Kelly, S. P., Mylavarapu, A. L., Holland, G. N., Coleman, A. L., Yu, F., Stephen Hsu, M., Lum, F., & Gordon, L. K. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.001 · Cited by 60
Adverse Events in Cancer Immunotherapy
Abdel‐Wahab, N., Alshawa, A., & Suarez-Almazor, M. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_8 · Cited by 60
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Self-citationImmune checkpoint inhibitor-induced musculoskeletal manifestations
Angelopoulou, F., Bogdanos, D. P., Dimitroulas, T., Sakkas, L. I., & Daoussis, D. (2020) · Rheumatology International · doi:10.1007/s00296-020-04665-7 · Cited by 58
Valencia-Sánchez, C., & Ζεκερίδου, Α. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.642800 · Cited by 58
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 56
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
Kadota, H., Gono, T., Shirai, Y., Okazaki, Y., Takeno, M., & Kuwana, M. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0811-3 · Cited by 63
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash, J. G., Francis, F. F., & Farraye, F. A. (2021) · Europe PMC (PubMed Central) · Cited by 55
Sise, M. E., Seethapathy, H. S., & Reynolds, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0764 · Cited by 55
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 56
Calvo, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00454 · Cited by 54
Tabchi, S., Weng, X., & Blais, N. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.026 · Cited by 52
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
Cappelli, L. C., & Bingham, C. O. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41587 · Cited by 51
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Kaur, A., Doberstein, T., Amberker, R. R., Garje, R., Field, E. H., & Singh, N. (2019) · Medicine · doi:10.1097/md.0000000000017348 · Cited by 51
Kean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 50
PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
Byeon, S., Cho, J. H., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2020) · Cancer Medicine · doi:10.1002/cam4.2868 · Cited by 50
Sheng, I. Y. F., & Ornstein, M. C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202017 · Cited by 51
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known
Zheng, C., Huang, S., Lin, M., Hong, B., Ni, R., Dai, H., Lin, X., & Yang, J. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000063 · Cited by 49
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature
Hickmott, L., Peña, H. D. L., Turner, H. E., Ahmed, F., Protheroe, A. S., Grossman, A. B., & Gupta, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0480-y · Cited by 48
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J. M., Sosman, J. A., Long, G. V., & Clark, J. I.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- Dana-Farber Cancer Institute (US)
- The University of Sydney (AU)
- Roswell Park Comprehensive Cancer Center (US)
- Rutgers Cancer Institute (US)
- University Hospital Heidelberg (DE)
- Westmead Hospital (AU)
- Loyola University Medical Center (US)
- Corresponding author
- Johnson, Douglas B.
- ORCID
- Johnson, Douglas B.
- Sullivan, Ryan J.
- Ott, Patrick A.
- Carlino, Matteo S.
- Khushalani, Nikhil I.
- Ye, Fei
- Guminski, Alexander
- Puzanov, Igor
- Lawrence, Donald P.
- Buchbinder, Elizabeth I.
- Spencer, Kristen
- Bender, Carolin
- Lee, Jenny
- Kaufman, Howard L.
- Menzies, Alexander M.
- Hassel, Jessica C.
- Mehnert, Janice M.
- Sosman, Jeffrey A.
- Long, Georgina V.
- Clark, Joseph I.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-02-01
- Volume
- 2
- Issue
- 2
- Pages
- 234
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2193769500
- Cited by
- 642
- References
- 30
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 49 · 2023: 44 · 2022: 64 · 2021: 73 · 2020: 94 · 2019: 93 · 2018: 65 · 2017: 68 · 2016: 47
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K12 CA 0906525, K12CA090625)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, advanced melanoma, immune-related adverse events, immune-related colitis, immune-related pneumonitis, immune-related hepatitis, immune-related endocrinopathy, immune-related dermatitis, immune checkpoint inhibitors, immunosuppressive therapy, rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Female, Humans, Male, Melanoma, Middle Aged, Retrospective Studies, Risk Factors, Skin Neoplasms, Time Factors, Autoimmunity, Treatment Outcome, Risk Assessment, Patient Selection, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
